Direktif memperketatkan penggunaan rosiglitazone dan memperkukuhkan amaran berkaitan dengan risiko kesan advers kardiovaskular pada sisip bungkusan semua produk rosiglitazone termasuk produk kombinasi
- Posted By LIM SZE GEE
- Hits: 10177
National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.